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Genome-wide identification of the mechanism of ac-
tion (MoA) of small-molecule compounds character-
izing their targets, effectors, and activity modulators
represents a highly relevant yet elusive goal, with crit-
ical implications for assessment of compound effi-
cacy and toxicity. Current approaches are labor
intensive andmostly limited to elucidating high-affin-
ity binding target proteins. We introduce a regulatory
network-based approach that elucidates genome-
wide MoA proteins based on the assessment of the
global dysregulation of their molecular interactions
followingcompoundperturbation. Analysis of cellular
perturbation profiles identified established MoA
proteins for 70% of the tested compounds and eluci-
dated novel proteins that were experimentally vali-
dated. Finally, unknown-MoA compound analysis re-
vealed altretamine, an anticancer drug, as an inhibitor
of glutathione peroxidase 4 lipid repair activity, which
was experimentally confirmed, thus revealing unex-
pected similarity to the activity of sulfasalazine. This
suggests that regulatory network analysis can pro-
vide valuable mechanistic insight into the elucidation
of small-molecule MoA and compound similarity.INTRODUCTION
The mechanism of action of a compound (MoA) is defined as the
set of target and effector proteins necessary to produce its phar-macological effect in a specific cellular context. Its elucidation is
critical in assessing both on-target compound activity as well as
off-target effects associated with potential toxicity, thus
providing critical insight into the two major challenges of drug
development (Scannell et al., 2012). Since most compounds in
clinical trials fail due to toxicity or lack of efficacy (Wehling,
2009), any improvements in systematic MoA characterization
may increase the yield of pharmacological discovery pipelines.
MoA characterization remains a major challenge that is only
partially addressed by experimental and computational strate-
gies. Most experimental approaches rely on direct binding as-
says, such as affinity purification (Hirota et al., 2012; Ito et al.,
2010) or affinity chromatography (Aebersold and Mann, 2003).
These methods are labor-intensive and generally limited to the
identification of high-affinity binding targets, rather than of all
proteins responsible for compound activity. They may thus
miss important indirect effectors, as well as lower-affinity targets
responsible for both desirable and undesirable pharmacolog-
ical properties. For instance, compounds can be effectively
screened against all protein kinases, while missing equally rele-
vant targets, as shown by the recent reclassification of the MET
inhibitor tivantinib as a microtubule inhibitor (Basilico et al.,
2013). In addition, these assays work in vitro and may miss ef-
fects from tissue-specific interactions and signals.
Chemo-informatics methods have also been developed. Yet,
these are mostly designed to assess compound MoA similarity
or specific compound/target interactions (Keiser et al., 2009; Lo-
menick et al., 2009; Miller, 2002), by leveraging the integration of
structural and genomic information (Yamanishi et al., 2008), text-
mining algorithms (Li et al., 2009), or machine learning methods
for data-mining (Hansen et al., 2009). As such, they rely on
detailed three-dimensional structures of both compound and
target proteins or on prior literature or database knowledge ofCell 162, 441–451, July 16, 2015 ª2015 Elsevier Inc. 441
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Figure 1. Schematics of the DeMAND Algorithm
(A) DeMAND requires both a regulatory network and a set of gene expression profiles from compound perturbed and control samples, as an input.
(B) DeMAND evaluates the dysregulation of each interaction in the regulatory network.
(C) To evaluate interaction dysregulation co-expression scatter plots for the two interacting genes are smoothed using a Gaussian Kernel method to generate an
interaction probability density. The probability density difference before and after compound perturbation is evaluated using the KL-divergence. The top example
illustrates no change in probability density (i.e., no dysregulation). The other three examples illustrate various examples of compound dysregulation, including
correlation inversion, gain, and loss (top to bottom, respectively).
(D) The statistical significance of the KL-divergence is assessed by gene pair shuffling.
(E) The global dysregulation of each gene is determined by integrating the p values of all its network interactions, while accounting for their dependencies.
(F) DeMAND produces a list of all network genes and the statistical significance of their dysregulation.
See also Figure S1, Table S7, and Supplemental Experimental Procedures.relatedMoA compounds.More recently, assembly of large refer-
ence compendia by systematic gene expression profiles (GEP)
analysis of cells following compound perturbations has spurred
development of MoA analysis methods (Ganter et al., 2005;
Lamb et al., 2006; Wolpaw et al., 2011). In general, however,
these methods are mostly comparative in nature and thus poorly
suited to de novo MoA elucidation or to recognize subtle MoA
differences that may induce unexpected toxicity. Network-
based methods have also been recently proposed (Bansal
et al., 2006; di Bernardo et al., 2005; Gardner et al., 2003; Mani
et al., 2008). Rather than focusing on individual genes, these
methods perform integrative analyses over interacting gene sub-
sets or pathways. Yet, these methods either rely on prior knowl-
edge of the pathways that mediate compound activity, making
them unsuitable for genome-wide analyses, or require very large
samples sizes (n > 100), thus making them impractical even for
small compound libraries. As a result, there is still a pressing442 Cell 162, 441–451, July 16, 2015 ª2015 Elsevier Inc.need for experimentally validated methodologies for the de
novo prediction of genome-wide compound targets and effec-
tors or to mechanistically elucidate MoA proteins associated
with differential activity or toxicity.
To address this challenge, we introduce detecting mechanism
of action by network dysregulation (DEMAND), a hybrid compu-
tational and experimental approach for MoA analysis. DeMAND
elucidates compound MoA by interrogating tissue-specific reg-
ulatory networks using small-size GEP datasets (nR 6 samples)
representing in vitro or in vivo, compound perturbations (Fig-
ure 1). Using GEPs from human lymphoma cells perturbed with
libraries of 14 and 92 compounds, respectively, we systemati-
cally assessed the algorithm’s ability to infer known compound
targets (from public databases) and then experimentally vali-
dated novel compound activity effector and modulator predic-
tions (hereafter MoA-proteins). DeMAND identified established
MoA proteins for >70% of these compounds, as well as novel
proteins that were experimentally validated, such as RPS3A,
VHL, and CCNB1 for the mitotic spindle inhibitor vincristine
and JAK2 for mitomycin C. We also tested the algorithm’s ability
to assess compound MoA similarity. More than 50% of top
predicted compound pairs were confirmed by literature and
database analysis or by experimental validation. For instance
DeMAND identified altretamine, an unknown MoA compound,
as a novel GPX4 inhibitor based on predicted MoA similar to sul-
fasalazine, a system xc
 cystine-glutamate antiporter-mediated
GPX4 inhibitor (Yang et al., 2014).
DeMAND is freely available to the research community, both
as a Bioconductor package (Gentleman et al., 2004) and as a
web-based geWorkbench module (Floratos et al., 2010).
RESULTS
Overview of DeMAND Algorithm
Consider the regulon of a geneG, i.e., all its interactions (G4Gi)
with other genesGi, including transcriptional, signaling, and pro-
tein-complex interactions. If G belongs to a compound’s MoA,
then it is reasonable to assume that its regulon gene interactions
will be dysregulated by the compound. This can be optimally
assessed by measuring changes in the joint gene expression
probability density p(G,Gi), for each of its regulon genes. Such
analysis can capture direct effects on gene expression and
more importantly modulation of the interacting partner’s expres-
sion via either direct or indirect regulatory mechanisms (e.g.,
feedback loops). Consider for instance a transcription factor
regulating a set of targets. A targeted inhibitor will significantly
alter the joint expression probabilities p(G,Gi), as the expression
of the targets will be dysregulated even though the expression of
G is not generally affected (Figures 1 and S1; Experimental
Procedures).
The Kullback-Leibler divergence (KLD) (Kullback and Leibler,
1951) provides an ideal metric to quantitatively assess probabil-
ity density changes in one or more variables. From information
theory, the KLD is easily interpreted as the loss of information
resulting from using a probability density as a surrogate for
another. For each regulon interaction (G 4 Gi), we estimate
the KLD of each probability density p(G,Gi), before and after
compound perturbation. Their statistical significance is then
integrated, thus producing a global statistical assessment of
the compound-mediated dysregulation of G. To avoid overesti-
mating such integrative significance, due to interaction depen-
dencies, we use amodification of Brown’smethod that compen-
sates for the integration of correlated evidence (Brown, 1975). All
genes are then ranked based on their global KLD statistics.
To identify the regulon of each gene-product of interest, we
used a set of established network reverse engineering
algorithms (see Experimental Procedures). However, DeMAND
is agnostic to the specific approach and can use networks
generated by any alternative means, both computational and
experimental.
DeMAND Predictions Are Enriched in Established
High-Affinity Binding Targets
We first evaluated the accuracy of DeMAND-inferredMoA genes
for 14 selected compounds, using the perturbation dataset(DP14) from the DREAM/NCI compound synergy challenge
(Bansal et al., 2014). This includes 276 GEPs of diffuse large B
cell lymphoma cells (OCI-LY3), following perturbation with 14
distinct compounds, of which 11 have established primary tar-
gets (Supplemental Experimental Procedures; Table S1), and
DMSO as control media, at two concentrations and three time
points, in triplicate. The network for these analyses was pro-
duced as described in Lefebvre et al. (2010), using a published
dataset of 226 U133p2 GEPs representing both normal and tu-
mor-related human B cells (Basso et al., 2010) (Supplemental
Experimental Procedures). Although DeMAND is designed to
predict both compound targets (i.e., high-affinity binding pro-
teins) and effectors/modulators, its performance can only be
systematically benchmarked against the former, because gold-
standard datasets to systematically assess the latter are not
yet available.
DeMAND identified the known primary targets of 7 of the 11
tested compounds as statistically significant, at a 10% false dis-
covery rate (FDR) (Figure S2A; Table S2; Experimental Proce-
dures). Since the GEPs used in this analysis were obtained at
multiple time points (6 hr, 12 hr, and 24 hr), we further assessed
whether individual time points may be more informative. Intrigu-
ingly, several targets were best predicted at specific time points
(Figure S2B), consistent with expectations that compound activ-
ity may be mediated over different timescales. Yet, integration
over all time points performed as well or better than the optimal
time point for all but two compounds (monastrol and doxoru-
bicin). For these, the direct target was significant only when spe-
cific time point GEPs were used. In total, targets for 9 of the 11
compounds could be elucidated either frommulti-point or single
time point analysis. Replacing interaction dysregulation with the
differential expression of neighbors reduces the performance
(see Supplemental Experimental Procedures).
Differential expression analysis has been proposed to eluci-
date compound substrates (Ganter et al., 2005; Lamb et al.,
2006; Wolpaw et al., 2011). We thus compared DeMAND’s per-
formancewith differential expression analysis, by t test statistics.
DeMAND systematically outperformed t test analysis, except for
blebbistatin for which neither method identified myosin II as sta-
tistically significant (Figure S2A). Indeed, DeMANDhadan almost
5-fold better sensitivity in the top 100 predictions, compared to t
test analysis (15% versus 3%), which was highly statistically sig-
nificant (p = 5 3 104 and p = 0.06 by c2 test, respectively) (see
Supplemental Experimental Procedures and Figure 2A). Further-
more, any targets thatwere significant by t test analysiswere also
significant by DeMAND analysis, but not the opposite. Consid-
ering the full area under the receiver operator characteristic
(ROC) curve (AUC), DeMAND also consistently outperformed
the t test, AUC = 0.70 (p = 2 3 1016 by Fisher integration of
individual Mann-Whitney p values for each compound) versus
AUC=0.60 (p = 3.53 107), respectively, reflecting higher overall
sensitivity and specificity (Figure S2C).
To assess DeMAND’s performance on MoA proteins other
than high-affinity targets, we focused on two of the four com-
pounds, whose direct targets were missed, including campto-
thecin (a TOP1 inhibitor) and doxorubicin (a TOP2A inhibitor),
which severely disrupt DNA repair and mitosis. DeMAND
identified growth arrest and DNA damage-inducible gene 45ACell 162, 441–451, July 16, 2015 ª2015 Elsevier Inc. 443
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Figure 2. DP14 Dataset Analysis
(A) The average sensitivity (true-positive rate) for
identifying known direct targets in all DP14 com-
pounds, as a function of the number of top
selected predictions, using either DeMAND (blue +
yellow areas) or t test analysis (red + yellow areas).
DeMAND consistently outperforms t test. For
instance, DeMAND achieves 15% sensitivity
across the top 100 predictions, compared to only
3% for t test. Furthermore, virtually all targets that
are significant by t test analysis are also significant
by DeMAND analysis (no red area for up to 400
genes). In contrast, DeMAND identifies many tar-
gets that are missed by t test (large blue area).
(B) Comparative schematics of established MoA
genes for camptothecin, doxorubicin, and etopo-
side. Doxorubicin-specific DeMAND inferred MoA
genes are shownwith an orange background, while
common inferred MoA genes for all compounds
are shown with a purple background. The com-
mon genes include the core DNA-damage repair
machinery (GADD45A, PCNA, and CDNK1A) and
cell-cycle arrest genes (CCNB1, AURKA, PLK1).
Doxorubicin’s specific MoA includes KAT5, a
mediator of histone eviction.
(C) Rank of DNAdamage response genes across all
DP14 compounds. DeMAND predicts GADD45A,
the canonical DNA-damage-inducible gene and its
well-known partners CDKN1A, PCNA, CCNB1,
AURKA, and PLK1 among the most significant
genes only for the five DNA damaging agents (i.e.,
camptothecin, doxorubicin, etoposide, mitomycin
C, and vincristine).
See also Figure S2 and Tables S1 and S2.(GADD45A), cyclin-dependent kinase inhibitor 1A (CDKN1A),
proliferating cell nuclear antigen (PCNA), Aurora Kinase A
(AURKA), polo-like kinase 1 (PLK1), and cyclin B1 (CCNB1)
among the most statistically significant genes for both com-
pounds (mostly in the top 20), which are known key downstream
effectors of TOP1 and TOP2A inhibition (Figure 2B). DeMAND
therefore identifies key MoA proteins for both these com-
pounds. More specifically, GADD45A, an established DNA dam-
age response effector (Goldwasser et al., 1996), acts by forming
protein complexes with CDKN1A and PCNA, a processivity fac-
tor of DNA polymerase delta required for high-fidelity DNA repli-
cation and excision repair (Smith et al., 1994). In turn, if DNA
damage is detected, CDKN1A, PCNA, and GADD45A regulate
the activity of CCNB1 (a critical effector of the G2/M cell-cycle
checkpoint) (Zhan et al., 1999), PLK1, and AURKA (a mitosis
regulator) either at the RNA or protein level (Shao et al., 2006).
Of these six genes, only GADD45A and CDKN1A were differen-
tially expressed, albeit at a much lower rank.
DeMAND Identifies Specific Differences in Compounds
with Similar MoA
Detailed assessment highlighted key differences and common-
alities in DeMAND-inferred MoA of compounds with similar
targets, which were undetectable by t test analysis. For instance,
camptothecin (TOP1), doxorubicin (TOP2A), and etoposide
(TOP2A) are all topoisomerase (TOP) inhibitors, which induce444 Cell 162, 441–451, July 16, 2015 ª2015 Elsevier Inc.single or double strand breaks following covalent trapping of
the TOP-DNA cleavable complex (Gilbert and Hemann, 2010).
Consistently, DeMAND identified a significant common footprint
in their inferredMoA, as shown in the previous section. However,
it also identified highly specific effectors, such as KAT5/TIP60 for
doxorubicin (ranked fourth), suggesting potentially relevant MoA
differences (Figure 2B). Indeed, contrary to etoposide and camp-
tothecin, doxorubicin is also a strong DNA intercalator, inducing
KAT5-dependent histone acetylation and release from open
chromatin (histone eviction) (Choi et al., 2009; Ikura et al.,
2000), leading to cell-cycle arrest (Pang et al., 2013). Similarly,
DeMAND identified SIK1 as a doxorubicin-specific effector
(ranked 36th), which is required for cardiac progenitor cell main-
tenance (CPCs) (Romito et al., 2010), thus pinpointing the com-
pound’s key adverse event, i.e., cardiomyopathy followed by
congestive heart failure (Zhang et al., 2012b). Both KAT5 and
SIK1 were completely missed by t test analysis.
Finally, DeMAND successfully stratified compounds based
on MoA gene overlap, further emphasizing its specificity. For
instance, for all DNA damaging agents, including camptothecin,
doxorubicin, etoposide, mitomycin C, and vincristine, DeMAND
predicted GADD45A, the canonical DNA-damage-inducible
gene, and its well-known interactors (CDKN1, CCNB1, PCNA,
and AURKA) among the most significant genes (Figure 2C).
Yet, these genes were not significant for other compounds
(Figure 2C), confirming the algorithm’s specificity.
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Figure 3. Validation of Novel Effectors of Vincristine and
Mitomycin C
(A) Immunohistochemistry-based imaging of microtubule networks in cells
treated with DMSO, vincristine, non-target siRNA, and siRNA-targeting
RPS3A. Non-target siRNA is indistinguishable from DMSO controls. Both
vincristine and siRPS3A significantly alter the microtubule network in U-2-OS
cells (4 nM of vincristine for 24 hr). Images represent red channel intensity.
(B) Vincristine dose response curves in U-2-OS following transfection with
non-target siRNA (blue) or siRNA-targeting CCNB1 (orange), VHL (red),
NFKBIA (black), and RPS3A (green). RPS3A and CCNB1 silencing reduces cell
sensitivity to vincristine, while VHL silencing increases sensitivity by 2-fold. The
error bars indicate the SD from the mean using three replicates. See also
Supplemental Experimental Procedures and Table S3.
(C) Mitomycin C dose-response curves in OCI-LY3 normalized to DMSO
treatment (black) or following treatment with TG101348 (a JAK2 inhibitor), at
0.2 uM (green), 0.4 uM (cyan), and 0.6 uM (blue). JAK2 inhibition induces loss of
sensitivity to mitomycin C.Validation of Novel Effectors and Modulators of
Compound Activity
To assess whether DeMAND can identify novel compound effec-
tors andmodulators,we validated novel predictions for vincristine
and mitomycin C, an inhibitor of microtubule formation in mitoticspindle and an antineoplastic antibiotic, respectively. DeMAND
successfully identified the known high-affinity target of vincristine
(TUBB), as well as CCNB1, VHL, RPS3A, and NFKBIA, in the top
fivepredictions.WhileRPS3AandVHLareknown toaffectmitotic
spindle assembly (Jang et al., 2012; Thoma et al., 2009), and
CCNB1 is a microtubule activity marker, their function in medi-
ating/modulating vincristine’s activity is unknown.
Probing themicrotubule network with an anti-tubulin antibody,
following small interfering RNA (siRNA)-mediated silencing of
these genes, confirmed that loss of RPS3A (but not of VHL,
CCNB1, or NFKBIA) disrupts microtubules in adherent U-2-OS
cells (Figure 3A). To further validate the role of these genes in
mediating vincristine’s activity, we performed dose-response
curve assays in U-2-OS cells, following silencing of each gene
(Supplemental Experimental Procedures; Table S3). These as-
says confirmed that all of these genes, except for NFKBIA, are
key vincristine activity effectors and mediators. Specifically,
VHL silencing increased vincristine sensitivity by more than
2-fold (Figure 3B), while RPS3A and CCNB1 silencing had the
opposite effect. Thus, four out of five of the top DeMAND-
inferred genes were confirmed vincristine activity modulators,
including its primary target (TUBB), suggesting that, for some
compounds, false positive rates may be as low as 20%. None
of these genes were significant by t test analysis.
DeMAND also inferred the JAK2 kinase as an exclusive mito-
mycin C MoA protein (i.e., JAK2 was not significant by DeMAND
analysis for any other compound). This is of potential importance
since constitutive activity of JAK2 causes chemo-resistance
in lymphocytes (Gupta et al., 2012), while constitutive JAK2 ac-
tivity may also affect DNA damage, repair, and recombination
outcome (Hoser et al., 2003). Confirming the prediction, dose-
response curves for mitomycin C, following treatment with vary-
ing amounts of TG101348 (a JAK2 inhibitor), revealed highly sig-
nificant, dose-dependent antagonism between JAK2 inhibition
and mitomycin C activity (Figure 3C; Experimental Procedures).
Finally, we analyzed DeMAND-inferred results for rapamycin.
While DeMAND could not predict the highest-affinity targets,
MTOR and FKBP1A, many genes downstream of MTOR path-
ways (Hsieh et al., 2012) were highly enriched in the top
DeMAND-inferred genes (Figure S2E), including many ribosomal
genes. The only other compound with significant ribosomal gene
enrichment was cycloheximide, a known ribosomal activity in-
hibitor, thus further highlighting the algorithm’s specificity.
Algorithm Robustness and Requirements
We then benchmarked DeMAND’s performance as a function of
network accuracy and size, as well as of the number of samples
in the perturbation dataset. First, we compared the results ob-
tained using an independent B cell gene regulatory network, re-
constructed from a distinct dataset of 254 Affymetrix U95av2
GEPs (see Experimental Procedures). We tested the enrichment
of statistically significant DeMAND-inferred genes (FDR% 0.1),
using the U95av2 network, against those inferred using the
U133p2 network, byGene Set Enrichment Analysis (GSEA) (Sub-
ramanian et al., 2005). The analysis confirmed that DeMANDpre-
dictions were almost identical, independent of network model
(p < 1 3 109 by GSEA; Figure S3A). Furthermore, predictions
were virtually unaffected when up to 60% of the networkCell 162, 441–451, July 16, 2015 ª2015 Elsevier Inc. 445
Table 1. Thirteen Compound Perturbation Datasets from the
GEO Database
Compound Cellular Context GEO ID
Zoledronate metastatic breast cancer cell lines
(MDA-MB-231)
GSE33552
Valproic acid chronic lymphocytic leukemia
(patient-derived B cells)
GSE14973
Genistein breast cancer cell lines (MCF-7) GSE9936
S-Equol breast cancer cell lines (MCF-7) GSE9936
Estradiol breast cancer cell lines (MCF-7) GSE9936
Rituximab B cell non-Hodgkin’s lymphoma
cell lines (K422)
GSE7292
Thapsigargin lytic-permissive lymphoblastoid
cell lines
GSE31447
Fluvastatin metastatic breast cancer cell lines
(MDA-MB-231)
GSE33552
MALT1 inhibitor diffuse large B cell lymphoma
(patient-derived B cells)
GSE40003
Docetaxel breast cancer cell lines (MCF-7) GSE5149
g-Secretase
inhibitor
MCL cell lines GSE34602
Triptolide breast cancer cell lines (MCF-7) GSE28662
Actinomycin D breast cancer cell lines (MCF-7) GSE28662
See also Figure S4 and Table S4.interactions were randomly removed (Figure S3B; Experimental
Procedures). Similarly, predictions were virtually identical, as
long as six or more GEPs representative of compound perturba-
tion were used (Figure S3C; Supplemental Experimental Proce-
dures). Taken together, these data suggest that DeMAND is
highly robust to network noise and especially to false negative
interactions and that it can be applied to datasets with as few
as six treatment and six untreated controls GEPs.
We then selected 13 datasets representing compound pertur-
bations (GEO13) from the GEO database (Table 1; Table S4).
Only compounds with established targets with at least six treat-
ment/control GEPs were selected, including seven human
breast cancer and six human B cell lymphoma datasets. Con-
firming results on the DP14 dataset, DeMAND inferred known
direct targets for 62% of these compound perturbations
(FDR% 0.1; Figure S4A), while still significantly outperforming t
test-based methods (AUC = 0.82 versus 0.74, respectively, p
value = 2.2 3 1016 versus p value = 5.9 3 108, respectively,
by Fisher integration of individual Mann-Whitney p values for
each compound) (Figure S4B). Among top-predicted MoA pro-
teins, DeMAND again achieved 5-fold better performance
than t test (Figure S4C).
DeMAND-Inferred MoA Stratifies Pharmacological
Effect
We then assessed whether DeMAND-inferred MoA overlap was
predictive of pharmacological compound similarity. We first
computed the significance of MoA overlap for each DP14 com-
pound pair (FDR % 0.1 by Fisher’s exact test [FET]) (Figure 4A;
Table S5; Experimental Procedures). Among all 91 possible446 Cell 162, 441–451, July 16, 2015 ª2015 Elsevier Inc.compound pairs, the six most similar ones included only
topoisomerase inhibitors and other DNA-damaging agents
(etoposide, doxorubicin, camptothecin, and mitomycin C).
Thus, DeMAND successfully assessed high compound MoA
similarity between topoisomerase inhibitors and other DNA-
damaging agents even though it could not identify TOP1 or
TOP2A among the inferred MoA genes, suggesting that key
effector proteins may be as informative as direct targets in terms
of compound similarity.
To further evaluate this hypothesis, we applied the method to
a much larger compound perturbation dataset (DP92), repre-
senting GEPs from three B cell lymphoma cell lines (OCI-LY3,
OCI-LY7, and U-2932), following perturbation with 92 unique
FDA-approved, late-stage experimental, and tool compounds
(Table S6; Supplemental Experimental Procedures). Since only
three GEPs per compound and cell line are available in this data-
set, we used it only for compound-pair similarity assessment
(see Experimental Procedures).
DeMAND performance was objectively evaluated by com-
parison with three independent data sources: (1) compounds
sharing established targets, (2) compounds sharing therapeutic
and chemical characteristics, according to the Anatomical
Therapeutic Chemical (ATC) classification system, and (3) com-
pounds with correlated drug-response profiles, as assessed by
the Cancer Target Discovery and Development (CTD2) con-
sortium (Basuetal., 2013) (seeSupplementalExperimentalProce-
dures). The latter dataset recapitulates dose-response curve vec-
tors representing 338 unique compounds profiled against 257
distinct cancer lines.We evaluated the fraction of validated similar
pairs (precision), basedoneachof the three evidencedatasets, as
a function of the number of significant pairs (precision curves, Fig-
ure 4B).DeMAND-inferredpairswere highly enriched in pairs from
three evidence datasets, as assessed by each of the evidences
individually (i.e., p value = 2 3 108, 1.4 3 105, and 9 3 104,
by GSEA, for pairs sharing the same ATC class, common estab-
lished targets, and high dose-response vector correlation in the
CTD2 dataset, respectively; Figure S5A), and also when taken
together (GSEA p value = 7.6 3 107). For instance, 8 of the top
10 and 43 of the top 100 DeMAND-inferred pairs were validated
by at least one of the three datasets (p = 2.23 1016 by FET).
DeMAND outperformed predictions using similarity obtained
by overlapping statistically significant differential expressed
genes (e.g., by t test statistics) by consistently achieving higher
sensitivity at any precision value (Figure S5B). DeMAND also
outperformed another state of the art method, (MANTRA) (Iorio
et al., 2010), which uses mutual gene set enrichment analysis
(Subramanian et al., 2005) to compute similarity, again by
achieving higher sensitivity at almost any desired precision value
(Figure S5B).
Finally, we evaluated the correlation between compound-pair
similarity as predicted by each method and their CTD2-based
similarity. DeMAND prediction achieved significant Spearman
correlation (r = 0.59, p value = 7.8 3 105; Figure S5C), while
both the t test andMANTRAmethods did not achieve statistically
significant correlation (Figures S5D and S5E). Thus, DeMAND
could predict compounds with similar pharmacological effect
and activity profile using only the GEP following their treatment
in a single cell line.
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(A) Compound similarity is assessed based on the
statistical significance (by FET) of the overlap of
their DeMAND-inferred MoA proteins.
(B) DeMAND-inferred compound similarity in the
DP92 dataset is assessed by (a) the overlap of
known direct targets between two compounds
(orange), (b) compound sensitivity profile similarity
based on CTD2 data (green), (c) overlap in com-
pound classification, according to the Anatomical
Therapeutic Chemical (ATC) Classification (blue),
or (d) any of the above evidences (black).
See also Figure S5 and Tables S5 and S6.DeMAND Identifies GPX4 as a Novel MoA Effector for
Altretamine
We identified altretamine and sulfasalazine as the compound
pair with the highest DeMAND-inferred MoA similarity (p value =
9.91 3 1081), among all pairs where the MoA of at least one
compound was unknown. Altretamine is an FDA-approved anti-
neoplastic drug with no established targets or effectors. Instead,
sulfasalazine is an inhibitor of system xc
, the cystine-glutamate
antiporter (Dixon et al., 2014), required for the biosynthesis of
glutathione (GSH). Thus sulfasalazine inactivates enzymes that
rely on reduced glutathione (GSH) as a cofactor, including gluta-
thione peroxidase 4 (GPX4) (Dixon et al., 2012; Yang et al., 2014),
leading to toxic accumulation of lipid reactive oxygen species
(ROS).
We thus tested whether altretamine may also modulate
the system xc
-GPX4 pathway. U-2932 cells were treated with
altretamine and their GSH levels were assessed using Ellman’s
reagent (Figure 5A; Supplemental Experimental Procedures).
Sulfasalazine was used as a positive control for GSH depletion
in U-2932 cells, confirming depletion of GSH levels following
compound treatment. In contrast, altretamine did not deplete
GSH levels, even after doubling its IC50 at 24 hr concentration,
suggesting that the compound may target mechanisms down-
stream of GSH in this pathway. We thus treated U-2932 cells
with altretamine and prepared cell lysates for a liquid chromatog-
raphy-mass spectrometry (LC-MS)-based GPX4 assay. Phos-
phatidylcholine hydroperoxide (PC-OOH), a specific substrate
for GPX4 (Brigelius-Flohe´ and Maiorino, 2013), was added to
cell lysates and PC-OOH to PC-OH reduction was assessed
by the mass chromatogram of the [PC-OOH + H+] ion (m/z =
790.5). As shown in Figure 5B, lysates of untreated cells reduced
PC-OOH levels completely, leaving no residual signal for the
[PC-OOH + H+] ion (m/z = 790.5). In sharp contrast, lysates
from altretamine-treated cells displayed a significant [PC-
OOH + H+] signal, indicating that abrogation of PC-OOH
reduction was mediated by GPX4 inhibition (Experimental Pro-
cedures). Indeed, since GPX4 is the only enzyme capable of
reducing lipid hydroperoxides (Yang et al., 2014), GPX4 inhibi-
tion is necessary to increases lipid-ROS levels (Thomas et al.,
1990). As expected, both sulfasalazine and altretamine were
confirmed to induce lipid-ROS accumulation in U-2932 cells,
as assessed by BODIPY-C11 staining and flow cytometry
(Figure 5C; Experimental Procedures). Thus, DeMAND correctlypredicted the unexpected mechanistic similarity between the
MoA of two previously unrelated drugs (Figure 5D), showing
altretamine as a new GPX4 inhibitor and suggesting a potential
mechanism for its antineoplastic activity.
DISCUSSION
DeMAND elucidates compound MoA by assessing com-
pound-mediated dysregulation of gene-gene interactions on a
genome-wide basis, from gene expression profiles of compound
perturbations. DeMAND reliably identifies compound targets, ef-
fectors, and activity modulators, allowing effective assessment
of compound MoA and MoA similarity. Indeed, DeMAND identi-
fied known and novel MoA genes for vincristine, mitomycin C,
and altretamine that were experimentally validated. DeMAND
also elucidated a novel MoA for altretamine, confirming its pre-
dicted similarity to sulfasalazine.
DeMAND was shown to be highly robust to network and sam-
ple variability. More importantly, unlike previous methods (di
Bernardo et al., 2005; Mani et al., 2008), DeMAND can reliably
predict compound MoA using as few as six control and six
perturbation samples. This allows unprecedented applicability
of the methods to elucidate MoA for novel developmental com-
pounds within specific cellular contexts of interest, including
in vivo.
DeMAND leverages integration of GEPs obtained at multiple
time points and at multiple compound concentrations, thus
simplifying experimental design when the precise concentration
or time points at which the MoA may be revealed is unknown.
Indeed, absent prior knowledge, compound MoA was optimally
revealed by integrating multi-time-point compound perturba-
tions for all but two of the tested compounds (Figure S2B).
DeMAND predictions are highly specific, allowing classifica-
tion of compounds into groups of similar function and identifi-
cation of pathways that are relevant to compound MoA. For
instance, for DNA-damaging compounds (camptothecin, doxo-
rubicin, etoposide, vincristine, and mitomycin C), DeMAND
correctly predicted several of the hallmark genes involved in
DNA-damage-induced response. The specificity was evidenced
by the fact that relevantMoA proteinswere inferred only for DNA-
damage inducing compounds and not for any other compound
(including compounds exhibiting significant polypharmacology
like H-7 dihydrochloride or cycloheximide). In other examples,Cell 162, 441–451, July 16, 2015 ª2015 Elsevier Inc. 447
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C Figure 5. DeMAND Identifies the MoA of Al-
tretamine
(A) GSH concentration following treatment of cells
by negative control (DMSO, gray), sulfasalazine as
a positive control (red), and altretamine (blue)
show that sulfasalazine reduces active GSH levels
compared to control, while altretamine results in
activeGSH levels indistinguishable from the control.
(B) The level of a GPX4-specific substrate (PC-
OOH) is measured by mass spectrometry (a)
without cell lysate (gray), (b) with untreated cell
lysate (green), and (c) with cell lysate from altret-
amine-treated cells (blue). PC-OOH levels in al-
tretamine-treated cells are similar to no-lysate and
markedly different from untreated lysate, indicating
that altretamine inhibits GPX4 activity.
(C) Lipid reactiveoxidativespecies (ROS) levelswere
measured by flow cytometry using DMSO-treated
cells (blackcurve,ascontrol) andcompound-treated
cells (red curve). Both altretamine and sulfasalazine
significantly increases lipid-ROS levels, confirming
the predicted similarity in their functional effect.
(D) Sulfasalazine is a known inhibitor of the System
xc
 cystine/glutamate antiporter. Its downstream
effect on Glutathione (GSH) and GPX4 leads to
accumulation of lipid ROS. DeMAND predicted
significant similarity between sulfasalazine and al-
tretamine and GPX4 but not GSH as altretamine-
specificMoAproteins, as experimentally confirmed
panels (A–C).high MoA specificity was shown for doxorubicin, where
DeMAND identified KAT5, consistent with recent findings
of KAT5-mediated histone eviction, as well as SIK1, a gene
required for cardiac progenitor cells maintenance, providing a
potential mechanistic link between doxorubicin and its known
cardiac toxicity. Critically, SIK1 was also detected in the MoA
of other DNA damaging agents, albeit at much lower rank/signif-
icance, suggesting that these compounds should also be moni-
tored for cardiac toxicity. Taken together, these findings suggest
that the algorithm is equally effective in predicting both direct tar-
gets and indirect compound effectors, thus helping elucidate
both on-target pharmacology and off-target toxicity. Overall,
DeMAND identified known MoA proteins for >70% of tested
compound, while experimental validation suggests that false
discovery rates (FDR) may be as low as 20%, although more
extensive FDR estimate is impossible at this time because com-
pound MoA in databases is largely incomplete, producing signif-
icant FDR overestimate. For instance, following experimental
validation, FDR for vincristine went from 80%, as only TUBB
was an established compound target/effector, to 20%.
DeMAND relies on the existence of high quality context-spe-
cific gene regulatory networks, which may represent a limitation
for specific cellular contexts. However, given the abundance of
data generated by large-scale projects such as the Cancer
Genome Atlas (TCGA) and other related consortia, as well as
the availability of increasingly accurate and comprehensive
methods for context-specific network reverse engineering (Cal-
ifano et al., 2012; Zhang et al., 2012a), this limitation is at best
temporary. However, network availability does not guarantee
identification of MoA proteins that are poorly represented. For
instance, for blebbistatin (a myosin II inhibitor), using the448 Cell 162, 441–451, July 16, 2015 ª2015 Elsevier Inc.U95av2 network, DeMAND identified PTK2B, GRB2, and FYN,
all of which are both direct regulators of myosin II phosphoryla-
tion and responders to myosin II perturbation (Sieg et al., 1998)
(Figure S2D). Yet, due to lack of GRB2 representation in the
U133p2 network, this gene could not be inferred. It is also impor-
tant to highlight that DeMAND analysis of the DP14 and DP92
datasets, using a high quality context-free network from the
STRING database (Franceschini et al., 2013), was still able to
identify ubiquitous targets and effectors (e.g., those involved in
cell-cycle and DNA damage repair mechanisms) with high preci-
sion and sensitivity, but exhibited lower performance both in
compound similarity analysis and in the identification of genes
with context-specific function/expression. This suggests that
non-context-specific networks can still be used for DeMAND
analyses, albeit with an increase in false positive and negative
predictions.
An important, albeit not critical, limitation of the current meth-
odology is the lack of prediction of compound activity sign, i.e.,
whether a compound will induce increase or decrease in an
inferred MoA protein activity. Conversely, the method cannot
predict whether inhibiting an inferredMoAprotein will likely either
increase or decrease drug activity. Presently, the only way to
resolve this question is by follow-up experimental assays. In
addition, the need for at least six GEPs at multiple concentra-
tions and time points is a potential limitation when assessing
MoA for large compound libraries. Despite these limitations,
however, DeMAND has proven highly effective in the de novo
identification of context-specific targets and effectors for arbi-
trary compounds of interest, providing important insight into
the prioritization of novel compounds for development, or into
the repositioning of previously approved compounds.
EXPERIMENTAL PROCEDURES
Networks Used in the Analysis
We generated context-specific gene-regulatory networks with both protein-
DNA and protein-protein interactions (Table S7). The analysis used both
context-specific GEPs and context-independent information from multiple
experimental and computational databases, which was integrated into a final
interactome using Naive Bayes Classifiers (see Lefebvre et al. [2010] and
Supplemental Experimental Procedures for detailed information). B cell-
and breast cancer-specific networks as well as the STRING database can
be downloaded from http://wiki.c2b2.columbia.edu/califanolab/index.php/
Software/DeMAND.
Evaluating Interaction Dysregulation
For each pair of interacting genes in the network, we compute a two-dimen-
sional probability density from their discrete rank-transformed expression in
a given condition (treatment or control), by Gaussian kernel smoothing, using
Silverman’s approach (Silverman, 1986). The sum of the Gaussian probabili-
ties densities from treatment samples, computed at each point of the discrete
rank space, provides the perturbation probability distribution P, while that from
control samples provides the control probability distribution Q. The distance
between the two discrete probability distributions is evaluated using a sym-
metric form of the Kullback-Leibler divergence (KLD), obtained by averaging
KLD (PjQ) and KLD (QjP).
KLD statistical significance is determined using a null distribution generated
by 105 KLD values generated from random gene pairs (regardless of whether
they share a network edge), providing individual edge dysregulation p values.
These are integrated across all the interactions in a specific gene regulon,
using the Fisher’s method, and corrected using a modification of Brown’s
method for correction of p value dependence (Brown, 1975), using the
covariance between the residuals from a linear fit to the common gene, a
(Figure S1A). A more detailed description of this method is available in the
Supplemental Experimental Procedures.
Determining Known Direct Targets of Compounds
Established targets for tested compounds were obtained from DrugBank
(Wishart et al., 2008), MATADOR (Gu¨nther et al., 2008), and literature searches.
For MATADOR, only genes annotated as ‘‘direct’’ or ‘‘direct-indirect’’ were
considered as compound targets, while genes labeled as ‘‘indirect’’ were dis-
carded. For a list of compound targets see Table S1.
Assessing Drug Similarity
To evaluate compound similarity, we first selected statistically significant MoA
genes (FDR% 0.1) for each compound. We then computed the significance of
their overlap by FET analysis. Many genes were not significant for any com-
pounds, thus biasing this analysis. To reduce this effect, we removed these
genes from the analysis. Notably this correction did not affect compound
pair ranking but only their absolute similarity p values, by avoiding p value
underestimation.
To compute similarity p values using the DP92 dataset we calculated
p values for each of the three cell lines independently and used Fisher’s
method to combine them.
Robustness Analysis
To evaluate the effect of network accuracy on DeMANDs’ performance, we
gradually removed interactions at random, in 10% increments and compared
the overlap of significant perturbed and unperturbed MoA protein predictions
by FET analysis. To evaluate the effect of sample size, we subsampled i sam-
ples (i = 3..18) from the compound-treated and from the control samples and
compared these results with the result obtained using all samples. Both ana-
lyseswere performed independently on each of the 14 compounds in theDP14
dataset. See the Supplemental Experimental Procedures for additional infor-
mation and Figure S3 for the results of the analysis.
Cell Culture
Diffuse large B cell lymphoma (DLBCL) OCI-LY3 and OCI-LY7 cells were ob-
tained from University Health Network (Toronto, Canada); the U-2932 DLBCLcell line was purchased from the Leibniz-Institute DSMZ German Collection of
Microorganisms and Cell Cultures; the U-2-OS osteosarcoma cell line was ob-
tained from ATCC (ATCC HTB-96). OCI-LY3, OCI-LY7, U-2932 cells were
cultured in Iscove’s modified Dulbecco Medium (IMDM) supplemented with
10% fetal bovine serum at 37C in a 5% CO2 atmosphere. U-2-OS cells
were cultured in McCoy’s 5A medium, supplemented with 10% fetal bovine
serum.
Dose-Response Curves
The 92 compounds were selected based on primary activity screen of FDA-
approved, late-stage experimental and tool compounds. OCI-LY3, OCI-LY7,
and U-2932 cells were seeded in white tissue culture-treated 96-well plates,
at a density of 53 104 cells per well in 100 ml total volume using the Janus auto-
mated liquid handling system (Perkin Elmer). After 12 hr of incubation at 37C,
plates were allowed to cool to room temperature, prior to compound addition
via the Janus. Compoundswere diluted in DMSO as a 7-point dilution curves in
a stock plate, 1 ml of these stock solutions where transferred into assay plates,
in triplicate. Thesewere subsequently placed on an orbital shaker for 5min and
then back in the incubator. At 24 hr, plates were removed from the incubator
and equilibrated to room temperature before addition of 50 ml of CellTiter-
Glo Luminescent Cell Viability Assay (Promega) per well. Plates were shaken
5 min on an orbital shaker before data acquisition in an Envision (PerkinElmer)
(0.5 s read time, enhanced luminescence). IC20 values were assessed using a
four parameter fit model (IDBS Activity Base).
Compound Treatment for Gene Expression Profiling
Cells were seeded in tissue culture-treated 96-well plates at a density of 5 3
104 cells per well using the Janus automated liquid handling system (Perkin
Elmer). They were then treated with the 24 hr IC20 of each compound (by
DMSO dilution) for 6 hr, 12 hr, and 24 hr at 37C, 5% CO2 under humidified
conditions. For each compound/condition combination one single data point
was analyzed and 0.2% DMSO vehicle-treated samples were used as con-
trols. Viability assay was run in parallel to monitor the compound effectiveness.
Generation of Gene Expression Profiles
Total RNA was isolated with the RNAqueous-96 Automated Kit (Ambion)
on the Janus automated liquid handling system (Perkin Elmer), quantified
by NanoDrop 6000 spectrophotometer and quality checked by Agilent
Bioanalyzer. A total of 300 ng of each of the samples with an RNA integrity
(RIN) value >7 were converted to biotinylated cRNA with the Illumina
TotalPrep-96 RNA Amplification Kit (Ambion) using a standard T7-based
amplification protocol and hybridized on the Human Genome U219 96-Array
Plate (Affymetrix). Hybridization, washing, staining, and scanning of the array
plates were performed on the GeneTitan Instrument (Affymetrix) according
to manufacturer’s protocols.
GPX4 Enzymatic Activity Assay
GPX4 enzymatic activity assay was performed as described in Yang et al.
(2014). Briefly, 13 106 cells were re-suspended in the cell lysis buffer. Sonicat-
ion was used to make cell lysates followed by centrifugation at 14,000 rpm for
10 min. Protein concentration of the cleared cell lysates was determined using
a Bradford protein assay (Bio-Rad). Two hundred micrograms of cellular
proteins was mixed with phosphatidyl choline hydroperoxide (PC-OOH),
the GPX4-specific substrate, and reduced glutathione, a GPX4 cofactor. The
mixture was incubated at 37C for 30 min followed by lipid extraction using
a chloroform:methanol (2:1) solution. The lipid extract was evaporated using
a rotary evaporator and re-dissolved in 100% ethanol before injecting into
LC-MS instrument for PC-OOH quantitation.
Analysis of Lipid ROS Generation
U-2932 cells (23 105) were seeded in 6-well plates and incubated at 37C for
16 hr. Cells were treated with test compounds for the indicated time, then har-
vested, pelleted, and washed once with PBS. For lipid ROS detections, cells
were re-suspended with Hanks balanced salt solution (HBSS, Life Technolo-
gies) containing C11-BODIPY (581/591) (2 mM) (Life Technologies) and incu-
bated for 10 min at 37C. Cells were then pelleted, re-suspended in 500 ml
HBSS, strained through 40-mM cell strainer (BD Falcon), and analyzed usingCell 162, 441–451, July 16, 2015 ª2015 Elsevier Inc. 449
BD Accuri C6 flow cytometer (BD Biosciences). C11-BODIPY signal was
measured using FL1 channel. Experiments were done in biological triplicates,
and a representative result was shown.
Co-treatment with Mitomycin C and a JAK2 Inhibitor
The JAK2-selective inhibitor TG101348 (Wernig et al., 2008) and Mitomycin C
were purchased from Selleckchem and Tocris Bioscience, respectively, and
were dissolved in DMSO. OCI-LY3 cells were treated with the indicated com-
pounds in 96-well plates and their growth was determined using the CellTiter-
Glo Luminescent Cell Viability Assay (Promega). Typically, 30,000 OCI-Ly3
cells per well in 200 ml of growth medium were grown for 48 hr in the presence
or absence (DMSO alone) of the desired compounds and then assayed with
CellTiter Glo according to manufacturer’s instructions.
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